SYNAPTOGENIX INC (SNPX)

US87167T2015 - Common Stock

0.85  -0.04 (-4.55%)

News Image
3 months ago - Synaptogenix, Inc.

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
5 months ago - InvestorPlace

Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?

With Synaptogenix’s clinical trial failure regarding its Alzheimer's drug candidate, SNPX stock tumbled on the broader implications.

News Image
5 months ago - Seeking Alpha

SNPX stock falls as Phase 2 trial for Alzheimer’s candidate fails (NASDAQ:SNPX)

Synaptogenix, Inc. (SNPX) shares crashed Friday after announcing that its Phase 2 trial for Alzheimer's disease candidate Bryostatin-1 did not meet the main goal. Read the full story here.

News Image
5 months ago - Synaptogenix, Inc.

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
8 months ago - Synaptogenix, Inc.

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
10 months ago - Synaptogenix, Inc.

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

News Image
10 months ago - Synaptogenix, Inc.

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

News Image
10 months ago - Synaptogenix, Inc.

Synaptogenix Announces Corporate Update Conference Call

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

News Image
10 months ago - Synaptogenix, Inc.

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix to Present at the Cell Symposium

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

News Image
a year ago - Synaptogenix, Inc.

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

News Image
a year ago - BusinessInsider

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

NEW YORK, March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeu...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders,...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...

News Image
a year ago - Synaptogenix, Inc.

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...